William J. Newell - Sep 24, 2021 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
CEO, Director
Signature
/s/ Edward C. Albini as attorney-in-fact for William Newell
Stock symbol
STRO
Transactions as of
Sep 24, 2021
Transactions value $
-$254,201
Form type
4
Date filed
9/28/2021, 06:58 PM
Next filing
Jan 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STRO Common Stock Gift $0 -105K -56.47% $0.00 80.7K Jul 1, 2021 Direct
transaction STRO Common Stock Gift $0 +105K $0.00 105K Jul 1, 2021 By William J. Newell Family Trust DTD 03/15/2019 F1
transaction STRO Common Stock Options Exercise $0 +25.3K +31.3% $0.00 106K Sep 24, 2021 Direct
transaction STRO Common Stock Tax liability -$254K -13.2K -12.48% $19.23 92.7K Sep 24, 2021 Direct F2
holding STRO Common Stock 10.6K Sep 24, 2021 By Newell Family Revocable Trust DTD 08/14/2008 F3
holding STRO Common Stock 26.1K Sep 24, 2021 By Taluswood Partners, L.P. F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Restricted Stock Unit (RSU) Options Exercise $0 -25.3K -100% $0.00* 0 Sep 24, 2021 Common Stock 25.3K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities are held of record by the reporting person as trustee of the William J. Newell Family Trust DTD 03/15/2019.
F2 Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.
F3 The securities are held of record by the reporting person as trustee of the Newell Family Revocable Trust DTD 08/14/2008.
F4 The reporting person is the general partner of Taluswood Partners, L.P. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
F5 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F6 The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.